Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Wilma Pastori et al.|Molecular Cancer Therapeutics|2010Cited by 63
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic LeukaemiaAlessia Casolaro, Rachele Alzani, Josée Golay et al.|PLoS ONE|2013Cited by 34
Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrierClara Albanese, Marina Ciomei, Rachele Alzani et al.|British Journal of Pharmacology|2013Cited by 21
294 POSTER Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125Rachele Alzani, C. Mercurio, Clara Albanese et al.|European Journal of Cancer Supplements|2008Cited by 1
Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Unknown|2023Cited by 0